Your session is about to expire
← Back to Search
Belimumab for Graft-versus-Host Disease
Study Summary
This trial is testing whether the drug belimumab is safe and effective in preventing chronic GvHD following allogeneic hematopoietic cell transplantation (alloHCT).
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2018 Phase 3 trial • 80 Patients • NCT02119156Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have tested positive for hepatitis C.You have previously taken part in a study to prevent a specific type of immune response after a transplant.I am currently being treated for a long-term infection.You have evidence of a current or past hepatitis B infection in your blood.I have chronic GvHD at the time of signing up.I am 18 years old or older.I have severe acute graft-versus-host disease.I will receive a stem cell transplant from a donor who is a complete HLA match.I am allergic to components in belimumab, including proteins or antibodies.I do not have any severe illnesses or social situations that would stop me from following the study's requirements.I have had cancer other than skin or cervical cancer in the last 5 years.I have not used IV or IM antibiotics in the last 14 days.You have any other important abnormal test results as determined by the doctor.I haven't had rituximab or similar treatments in the last 3 months.You have a history of a weakened immune system, autoimmune disease, or long-term infection.My bone marrow transplant is successful and I am in complete remission.There is strong evidence that you may be at risk of harming yourself.You have been diagnosed with HIV.I have been diagnosed with a blood cancer.I am undergoing a bone marrow preparation treatment.I am receiving methotrexate and tacrolimus to prevent graft-versus-host disease.You do not have any remaining cancer cells in your body.I received a donor lymphocyte infusion for relapse or to maintain my transplant.My liver and kidney functions are within the required range.I can take care of myself and am up and about more than half of my waking hours.
- Group 1: Belimumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does this research project currently accept new participants?
"At present, no participants are being sought for this experiment. It was initially posted on May 16th 2018 and subsequently updated in October 10th 2022. If you're interested in additional trials, 169 studies with related illnesses have open enrollment while 17 of those focus on the effects of Belimumab."
How many participants will be enrolled in this clinical trial?
"Unfortunately, this trial has closed recruitment. It was initially released on May 16th 2018 and the last edit to its details occurred October 10th 2022. However, if you are interested in other trails there remain 169 studies searching for participants with related illness and 17 trials of Belimumab actively enrolling patients."
Has this trial been undertaken before, or is it a pioneering effort?
"Presently, there are 17 ongoing Belimumab trials spanning 36 urban centres and 15 nations. The initial trial for this medication began in 2012 with Human Genome Sciences Inc., a GSK Company, as its sponsor; the Phase 2 stage was ended after 93 participants were included. Subsequent to that pioneering study, 38 additional experiments have been performed."
Could you please elucidate the risk associated with Belimumab?
"Belimumab's safety and efficacy is not yet clinically established, resulting in an assigned score of 1."
Are there any published accounts of Belimumab's effectiveness in previous research?
"Currently, 17 studies are underway to evaluate the efficacy of Belimumab. 2 of those experiments have reached Phase 3 and they're being conducted in Beijing as well as 88 other medical centres."
Share this study with friends
Copy Link
Messenger